<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02046668</url>
  </required_header>
  <id_info>
    <org_study_id>13/WS/0232</org_study_id>
    <secondary_id>2013-002638-19</secondary_id>
    <nct_id>NCT02046668</nct_id>
  </id_info>
  <brief_title>The Effect of Spironolactone on Pain in Older People With Osteoarthritis</brief_title>
  <acronym>SPIR-OA</acronym>
  <official_title>A Randomised Placebo Controlled Trial. The Effect of Spironolactone on Pain in Older People With Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Dundee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arthritis Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Dundee</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study will obtain preliminary evidence on which to base sample size calculations&#xD;
      for a future trial of whether spironolactone (an aldosterone blocker) reduces knee pain in&#xD;
      older people with symptomatic OA knee when given in addition to usual analgesia. Aldosterone&#xD;
      is known to be pro-inflammatory, and spironolactone suppresses cytokine production in chronic&#xD;
      arthritis. This application builds on previous work by the applicants showing that&#xD;
      spironolactone significantly improved quality of life (particularly pain) in frail older&#xD;
      people. The investigators will recruit 86 people (aged 70 years or over) with well-defined OA&#xD;
      knee to 25mg spironolactone daily or to matching placebo for 12 weeks. The primary outcome is&#xD;
      the between group difference in change in WOMAC pain sub-score at 12 weeks. Secondary&#xD;
      outcomes are the WOMAC stiffness and physical function subscales and health related quality&#xD;
      of life (EQ-5D). Morning cortisol levels will be measured to assess the effect of&#xD;
      mineralocorticoid receptor blockade on glucocorticoid levels, which may mediate the&#xD;
      anti-inflammatory effect of spironolactone; and urinary CTX-II, and serum matrix&#xD;
      metalloproteinase-3 (MMP-3) will be measured as biomarkers as both are sensitive to the&#xD;
      effects of pharmacological interventions for osteoarthritis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Between group difference in change in WOMAC pain subscale (5 items)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Between group difference in change in WOMAC stiffness subscale.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Between group difference in change in WOMAC physical function subscales.</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Between group difference in change in health-related quality of life measured by EQ-5D questionnaire.</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>spironolactone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25mg spironolactone daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>spironolactone</intervention_name>
    <description>spironolactone 25mg daily for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>spironolactone</arm_group_label>
    <other_name>Aldactone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participant is willing and able to give informed consent&#xD;
&#xD;
          2. Community dwelling&#xD;
&#xD;
          3. Aged 70 years and over&#xD;
&#xD;
          4. Symptomatic idiopathic OA knee according to American College of Rheumatology clinical&#xD;
             and radiographic criteria (ie Knee pain - with or without crepitus and presence of&#xD;
             osteophytes on x ray)&#xD;
&#xD;
          5. To avoid floor effects, participants will require to have moderate (or more severe)&#xD;
             pain at screening in at least 2 out of 5 WOMAC pain score items&#xD;
&#xD;
          6. To have been in receipt (prescription or/and over the counter) of one or more&#xD;
             analgesic agents at a therapeutic dose for at least 2 months&#xD;
&#xD;
          7. Willing to have knee x-ray if one has not been taken in preceding 12 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinical diagnosis of symptomatic heart failure&#xD;
&#xD;
          2. History of inflammatory arthritis&#xD;
&#xD;
          3. Already taking spironolactone&#xD;
&#xD;
          4. Previous intolerance to spironolactone&#xD;
&#xD;
          5. Known allergies to spironolactone or lactose&#xD;
&#xD;
          6. Objection to taking capsules made from animal sourced gelatine&#xD;
&#xD;
          7. Taking oral NSAIDs (because of the increased risk of renal impairment when combined&#xD;
             with spironolactone)&#xD;
&#xD;
          8. Taking ACE inhibitors or ARBs (angiotensin II receptor antagonists). ARBs have many&#xD;
             properties similar to those of ACE inhibitors. Both will be exclusion because of the&#xD;
             increased risk of acute kidney injury and hyperkalaemia, and because our previous&#xD;
             study also excluded those on ACE inhibitors (and ARBs) and treatment was safe and well&#xD;
             tolerated.&#xD;
&#xD;
          9. Supine hypotension (supine systolic blood pressure &lt;100mmHg at screening)&#xD;
&#xD;
         10. Significant chronic kidney disease (eGFR&lt;40ml/min)&#xD;
&#xD;
         11. Serum sodium&lt;130mmol/l&#xD;
&#xD;
         12. Serum potassium&gt;5.0mmol/l&#xD;
&#xD;
         13. Symptomatic orthostatic hypotension (measured at screening)&#xD;
&#xD;
         14. Nursing home resident&#xD;
&#xD;
         15. Wheelchair bound&#xD;
&#xD;
         16. Participating in another clinical trial (other than observational trials and&#xD;
             registries) concurrently or within 30 days prior to screening for entry into this&#xD;
             study&#xD;
&#xD;
         17. Known contraindication to spironolactone therapy&#xD;
&#xD;
         18. Participant who is terminally ill, defined as less than 3 months expected survival&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marion ET McMurdo, MBChB, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Dundee</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miles Witham, BM BCh, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Dundee</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vera Cvoro, Mb CHB, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>NHS Fife</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NHS Fife</name>
      <address>
        <city>Kirkcaldy</city>
        <state>Fife</state>
        <zip>KY2 5AH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Tayside</name>
      <address>
        <city>Dundee</city>
        <state>Tayside</state>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/26413749</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>January 24, 2014</study_first_submitted>
  <study_first_submitted_qc>January 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2014</study_first_posted>
  <last_update_submitted>October 11, 2019</last_update_submitted>
  <last_update_submitted_qc>October 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis of knee</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

